Suchergebnisse - "Buti, Maria"

PubPharm (9)

1

Impact of hepatitis D reflex testing on the future disease burden : A modelling analysis

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2023

von Buti, M. | Domínguez-Hernández, R. | Palom, A. | +2

2

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D : Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference

enthalten in: Hepatology (Baltimore, Md.) | 2023

von Ghany, M. | Buti, M. | Lampertico, P. | +2

3

Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

enthalten in: Journal of hepatology | 2023

von Razavi, H. | Buti, M. | Terrault, N. | +89

4

Community Strategy for Hepatitis B, C, and D Screening and Linkage to Care in Mongolians Living in Spain

enthalten in: Viruses | 2023

von Palom, A. | Almandoz, E. | Madejón, A. | +10

5

Pilot hepatitis C micro-elimination strategy in Pakistani migrants in Catalonia through a community intervention

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2022

von Martró, E. | Ouaarab, H. | Saludes, V. | +10

6

The impact of COVID-19 on the cascade of care of HCV in the US and China

enthalten in: Annals of hepatology | 2022

von Yeo, Y. | Gao, X. | Wang, J. | +10

7

Letter to the editor : Standardization of HBV-RNA assay for the different phases of chronic hepatitis B is essential

enthalten in: Hepatology (Baltimore, Md.) | 2022

von Tabernero, D. | Cortese, M. | Rando-Segura, A. | +2

CommentOn: Hepatology. 2021 Jun;73(6):2167-2179. - PMID 33159329

8

Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA : Different quasispecies?

enthalten in: World journal of gastroenterology | 2021

von Garcia-Garcia, S. | Cortese, M. | Tabernero, D. | +15

9

One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease

enthalten in: Alimentary pharmacology & therapeutics | 2021

von Palom, A. | Sopena, S. | Riveiro-Barciela, M. | +14

CommentIn: Aliment Pharmacol Ther. 2021 Aug;54(4):519-520. - PMID 34331811

1
[1]